Seer Appoints Isaac Ro to its Board of Directors
Seer (Nasdaq: SEER), a pioneer in proteomic insights, has appointed Isaac Ro to its Board of Directors. Ro brings significant financial leadership experience and deep sector expertise in life science tools and diagnostics. Currently a Partner at Catalio Capital Management, Ro has an impressive track record including serving as Executive Chairman of Haystack Oncology (acquired by Quest Diagnostics), CFO of Sema4 during its public listing, and CFO of Thrive Earlier Detection (acquired by Exact Sciences).
Prior to these roles, Ro led U.S. Medical Technology and Life Science Tools equity research teams at Goldman Sachs from 2010 to 2019. He currently serves on the boards of PinkDx and PrognomiQ, bringing valuable experience to support Seer's growth and platform development initiatives.
Seer (Nasdaq: SEER), pioniere nelle analisi proteomiche, ha nominato Isaac Ro nel suo consiglio di amministrazione. Ro apporta una solida esperienza nella leadership finanziaria e una profonda conoscenza del settore degli strumenti per le scienze della vita e della diagnostica. Attualmente Partner presso Catalio Capital Management, vanta un curriculum di rilievo: è stato Executive Chairman di Haystack Oncology (acquisita da Quest Diagnostics), CFO di Sema4 durante la sua quotazione pubblica e CFO di Thrive Earlier Detection (acquisita da Exact Sciences).
In precedenza, dal 2010 al 2019, Ro ha guidato i team di ricerca azionaria per dispositivi medici e strumenti per le scienze biologiche negli Stati Uniti presso Goldman Sachs. Siede inoltre nei consigli di amministrazione di PinkDx e PrognomiQ, offrendo competenze preziose per sostenere la crescita di Seer e lo sviluppo della sua piattaforma.
Seer (Nasdaq: SEER), pionera en información proteómica, ha incorporado a su junta directiva a Isaac Ro. Ro aporta una destacada experiencia en liderazgo financiero y un profundo conocimiento del sector de herramientas para ciencias de la vida y diagnóstico. Actualmente es socio en Catalio Capital Management y cuenta con un historial notable: fue Executive Chairman de Haystack Oncology (adquirida por Quest Diagnostics), CFO de Sema4 durante su salida a bolsa y CFO de Thrive Earlier Detection (adquirida por Exact Sciences).
Antes de estos cargos, Ro dirigió los equipos de investigación de renta variable en dispositivos médicos y herramientas para ciencias de la vida en EE. UU. en Goldman Sachs entre 2010 y 2019. También forma parte de los consejos de PinkDx y PrognomiQ, aportando experiencia valiosa para apoyar el crecimiento y el desarrollo de la plataforma de Seer.
Seer (Nasdaq: SEER)는 단백질체학 분야의 선구자로서 아이작 로(Isaac Ro)를 이사회에 선임했습니다. 로는 강력한 재무 리더십과 생명과학 도구 및 진단 분야에 대한 깊은 전문 지식을 갖추고 있습니다. 현재 Catalio Capital Management의 파트너로 재직 중인 그는 탁월한 경력을 보유하고 있으며, Haystack Oncology의 Executive Chairman(해당 기업은 Quest Diagnostics에 인수), Sema4의 상장 당시 CFO, Thrive Earlier Detection의 CFO(Exact Sciences에 인수)를 역임했습니다.
그전에는 2010년부터 2019년까지 Goldman Sachs에서 미국 의료기기 및 생명과학 도구 분야의 주식 리서치 팀을 이끌었습니다. 또한 PinkDx와 PrognomiQ의 이사회에서 활동하며 Seer의 성장과 플랫폼 개발을 지원할 풍부한 경험을 제공합니다.
Seer (Nasdaq: SEER), pionnier des analyses protéomiques, a nommé Isaac Ro au sein de son conseil d'administration. Ro apporte une solide expérience en direction financière et une expertise approfondie dans les outils de sciences de la vie et le diagnostic. Actuellement associé chez Catalio Capital Management, il possède un parcours remarquable : Executive Chairman de Haystack Oncology (acquise par Quest Diagnostics), CFO de Sema4 lors de son introduction en bourse, et CFO de Thrive Earlier Detection (acquise par Exact Sciences).
Auparavant, de 2010 à 2019, Ro a dirigé les équipes de recherche actions pour la technologie médicale et les outils des sciences de la vie aux États-Unis chez Goldman Sachs. Il siège également aux conseils d'administration de PinkDx et PrognomiQ, apportant une expérience précieuse pour soutenir la croissance de Seer et le développement de sa plateforme.
Seer (Nasdaq: SEER), ein Vorreiter in der Proteomik, hat Isaac Ro in seinen Vorstand berufen. Ro bringt umfangreiche Erfahrung in finanzieller Führung sowie tiefes Branchenwissen im Bereich Life-Science-Tools und Diagnostik mit. Er ist derzeit Partner bei Catalio Capital Management und kann auf eine beeindruckende Laufbahn zurückblicken: Executive Chairman von Haystack Oncology (übernommen von Quest Diagnostics), CFO von Sema4 während des Börsengangs und CFO von Thrive Earlier Detection (übernommen von Exact Sciences).
Von 2010 bis 2019 leitete Ro die US-Equity-Research-Teams für Medizintechnik und Life-Science-Tools bei Goldman Sachs. Darüber hinaus sitzt er in den Aufsichtsräten von PinkDx und PrognomiQ und bringt wertvolle Erfahrung ein, um Seers Wachstum und Plattformentwicklung zu unterstützen.
- Addition of experienced financial leader with deep sector expertise in life science tools and diagnostics
- Board member brings successful track record in guiding companies through public listings and acquisitions
- Strategic appointment to support company's growth and platform development initiatives
- None.
REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors.
“We are excited to welcome Isaac to our board,” said Omid Farokhzad, Chair and CEO of Seer. “Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven track record of guiding companies through transformative growth will be invaluable as we continue to execute on key milestones and accelerate the impact of our platform.”
“I’m looking forward to working with the Seer team as they push the boundaries of deep, unbiased proteomics,” said Isaac Ro. “Seer has built an impressive innovation engine with significant runway ahead as they begin to unlock the full potential of their platform. I’m excited to support their efforts to deepen our understanding of the proteome and expand our understanding of human health.”
Mr. Ro is a Partner at Catalio Capital Management, where he has led multiple venture and private credit investments in breakthrough life science companies. He currently serves on the boards of PinkDx and PrognomiQ. Previously, he was Executive Chairman of Haystack Oncology, where he led the company through its successful acquisition by Quest Diagnostics in 2023. Prior to Catalio, Mr. Ro served as Chief Financial Officer of Sema4 (NASDAQ: WGS), where he guided the company through its public listing in 2021 and the acquisition of GeneDx. He also held the role of Chief Financial Officer of Thrive Earlier Detection, where he led the company’s launch and subsequent sale to Exact Sciences in 2020. Prior to Thrive, Mr. Ro led the U.S. Medical Technology and Life Science Tools equity research teams at Goldman Sachs from 2010 to 2019, and held a similar role at Leerink Partners prior to that. Mr. Ro earned his B.A. in History and was Pre-Med at Middlebury College.
About Seer
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with scale, speed, precision, and reproducibility. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others cannot. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.
Investor Inquiries:
Carrie Mendivil
investor@seer.bio
Media Contact:
Consort Partners
pr@seer.bio
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5d88d379-9741-4aa2-969d-1d4dbf12ecc2
FAQ
Who is Isaac Ro and what is his role at Seer (NASDAQ: SEER)?
What is Isaac Ro's experience in the healthcare and life sciences industry?
What other board positions does Isaac Ro currently hold?
Why did Seer (NASDAQ: SEER) appoint Isaac Ro to its board?
